Abstract:Inhibition of Bruton tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib and Pirtobrutinib have been clinically approved. All are covalent active site inhibitors, with the exception of the reversible active site inhibitor Pirtobrutinib. The large number of available inhibitors for the BTK target creates challenges in choosing the most appropriate BTKi for treatment. Side-by-side comparisons in CLL have shown that different inhibitors may differ in their treatment efficacy. Moreover, the nature of the resistance mutations that arise in patients appears to depend on the specific BTKi administered. We have previously shown that Ibrutinib binding to the kinase active site causes unanticipated long-range effects on the global conformation of BTK (Joseph, R.E., et al., 2020, https://doi.org/10.7554/eLife.60470). Here we show that binding of each of the five approved BTKi to the kinase active site brings about distinct allosteric changes that alter the conformational equilibrium of full-length BTK. Additionally, we provide an explanation for the resistance mutation bias observed in CLL patients treated with different BTKi and characterize the mechanism of action of two common resistance mutations: BTK T474I and L528W.

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on two aspects: 1. **The influence of BTK inhibitors on the conformation of the full - length BTK protein**: - Researchers explored how five clinically approved BTK inhibitors (Acalabrutinib, Zanubrutinib, Tirabrutinib, Pirtobrutinib) cause different allosteric changes after binding to the full - length BTK protein, thereby changing the overall conformational equilibrium of BTK. These changes not only affect the active site of BTK but may also affect the stability of its regulatory domain. 2. **The mechanism of BTK inhibitor - resistant mutations**: - The paper also analyzed the bias phenomenon of resistant mutations in patients with chronic lymphocytic leukemia (CLL) after receiving different BTK inhibitor treatments. Specifically, researchers explained why certain BTK inhibitors lead to specific resistant mutations (such as T474I and L528W), while other inhibitors lead to different mutations (such as C481S). In addition, they also studied in detail the specific mechanisms of the two common resistant mutations, T474I and L528W. ### Specific problem analysis 1. **The influence of BTK inhibitors on the conformation of BTK**: - **Methods**: Researchers used nuclear magnetic resonance (NMR) and hydrogen - deuterium exchange mass spectrometry (HDX - MS) techniques to evaluate the influence of BTK inhibitors on the conformation of the full - length BTK protein. - **Findings**: - Acalabrutinib, Zanubrutinib, and Tirabrutinib destabilize the auto - inhibitory conformation of BTK, similar to the effect of Ibrutinib. - Pirtobrutinib stabilizes the compact auto - inhibitory conformation of BTK, which is the first time this phenomenon has been observed. - The conformational changes caused by each inhibitor are unique and cannot be predicted solely from the crystal structure. 2. **The mechanism of resistant mutations**: - **Methods**: Through in vitro kinase activity assays, HDX - MS and NMR techniques, the effects of T474I and L528W mutations on BTK activity and overall conformation were studied. - **Findings**: - **T474I mutation**: Reduces the catalytic activity of BTK but does not increase its activity. HDX - MS shows that this mutation increases the kinetics of the N - lobe β2 - β3 strand and the activation loop of the kinase domain, which may affect drug binding. - **L528W mutation**: Completely inactivates BTK. HDX - MS shows that this mutation stabilizes the auto - inhibitory conformation of BTK. - **L528W mutation activates HCK**: Although the L528W mutation inactivates BTK, it can activate the SRC family kinase HCK, thereby maintaining BCR signaling. ### Conclusion Through these studies, the authors not only revealed the specific effects of different BTK inhibitors on the conformation of BTK but also explained why different inhibitors lead to different resistant mutations. These findings are helpful for better understanding the therapeutic effects of BTK inhibitors and provide important references for future drug design and treatment strategies.

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies

New means and challenges in the targeting of BTK

Targeting Bruton’s Tyrosine Kinase in CLL

Targeting Bruton's Tyrosine Kinase in CLL

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

Abstract 4669: Differential preclinical activity of Bruton tyrosine kinase inhibitors (BTKis) against BTK resistance-associated mutations

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

BTK inhibitors: past, present, and future

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling